Clinical Research

Log InManage your Clinical Research Studies SubscribeSubscribe

Eligibilty

Participant's Age Group



 More options for age range

Dates

More options for date range

Names

Showing 1 - 5 of 11 results
Page 1 of 3 Previous Page Next Page 

Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH)

Principal Investigator: Sif Hansdottir, MD

This is a Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo as Add-on Therapy in Symptomatic Subjects with Pulmonary Arterial Hypertension (PAH).

 

Please refer to www.clinicaltrials.gov identifier NCT01457781 for further information. 

age group:18 to 80 years trial start date:April 20, 2012
Gender Preference:none Trial End Date: June 14, 2013
Contact Info:

Pulmonary Hypertension Program

Page Scovel, RN

phone:  319-356-1028

fax:  319-356-7087

email:  page-scovel@uiowa.edu
Keywords: Heart ; High blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension

Evaluate the Safety and Tolerability of Oral BAY63-2521

Principal Investigator:Sif Hansdottir, MD

Chest -2 Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1

Riociguat (BAY63-2521)

BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study

for more information go to www.clinicaltrials.gov Identifier NCT00910429

age group:18 to 80 years trial start date:April 11, 2012
Gender Preference:none Trial End Date: September 1, 2014
Contact Info:

Pulmonary Hypertension Program

Cynthia Larew RN  319-356-1028 pager # 2123

cynthia-larew@uiowa.edu

 
Keywords: Chest -2 Long-term Extension ; Chronic Thromboembolic Pulmonary Hypertension ; CTEPH ; Heart ; High blood pressure in lungs ; PH ; pulmonary hypertension

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program (PAH QuERI Ext)

Principal Investigator: Sif Hansdottir, MD

This program intends to improve the management of pulmonary arterial hypertension (PAH) patients through an evidence-based approach aimed at achieving optimal World Health Organization (WHO) functional class (FC): 1. Improving FC III & IV patients to FC II, 2. Improving FC II patients to FC I, and 3. Maintaining FC II & FC I patients.

 

Please refer to www.clinicaltrials.gov identifier NCT01389206 for more information.

age group:18 to 99 years trial start date:June 1, 2011
Gender Preference:none Trial End Date: March 31, 2016
Contact Info:

Pulmonary Hypertension Program

Cynthia Larew, RN

phone:  319-356-1028

fax:  319-356-7087

email:  cynthia-larew@uiowa.edu
Keywords: Heart ; High blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension

Assessing Nasopharyngeal and Pulmonary Adverse Events that may be Associated Certain Medications

Principal Investigator:Sif Hansdottir, MD

Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution 

Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.

Please refer to www.clinicaltrials.gov for more information identifier NCT01266265

age group:1 to 99 years trial start date:April 11, 2011
Gender Preference:none Trial End Date: February 4, 2014
Contact Info:

Pulmonary Hypertension Program

Cynthia Larew RN 319-356-1028  pager # 2123

cynthia-larew@uiowa.edu
Keywords: Enter keyword ; Heart ; inhaled prostacyclin ; observational study ; PAH ; Pulmonary Arterial Hypertension ; pulmonary hypertension ; treprostinil sodium ; Tyvaso

A Study to Test the Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular Systolic Dysfunction (LEPHT)

Principal Investigator: KellyAnn Light-McGroary, MD

The aim of this study is to assess whether increasing oral doses of Riociguat are safe and improve the well-being, symptoms and outcome in patients with pulmonary hypertension associated with left ventricular systolic dysfunction

This study is closed to enrollment and is in follow-up phase.

Please refer to www.clinicaltrials.gov identifier NCT01065454 for more information. 

age group:18 to 80 years trial start date:April 1, 2010
Gender Preference:none Trial End Date: May 31, 2017
Contact Info:

Cardiomyopathy Treatment Program

Page Scovel, RN

phone:  319-356-1028

fax:  319-356-7087

email:  page-scovel@uiowa.edu
Keywords: cardiac disease ; Cardiomyopathy ; Congestive heart failure ; Heart ; Heart failure ; Left ventricular systolic dysfunction ; Pulmonary hypertension ; Pulmonary hypertension associated with left heart
Page 1 of 3
« 1 2 3 » 
Results per page 5 | 15 | 25

Copyright © 2013 The University of Iowa. All Rights Reserved.